The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among species
The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among species
复制标题
DOI：
10.1016/j.vaccine.2010.04.036
复制
发表时间：
2010-06-17
期刊：
影响因子：
5.5
通讯作者：
Miura, Kazutoyo
中科院分区：
文献类型：
--
作者：
Cheru, Lediya;Wu, Yimin;Miura, Kazutoyo
恶性疟原虫表面蛋白25（Pfs 25）是传播阻断疫苗（TBVs）的候选者。抗Pfs 25抗体在膜饲养试验中阻断卵囊的发育，并且我们已经表明活性与抗体滴度相关。在本研究中，我们纯化Pfs 25特异性IgG，将抗体滴度转换为p μ g/mL，并测定抑制50%卵囊发育所需的抗体量（IC 50）。小鼠、兔、猴和人的IC 50分别为15.9、4.2、41.2和85.6 μ g/mL，种属间差异显著。兔、猴和人抗Pfs 25血清与鼠抗Pfs 25单克隆抗体的竞争模式不同，且4种动物间抗体的亲合力也不同。这些数据表明，从评估TBV候选物效力的动物研究中获得的信息可能难以转化为人类免疫。(C)2010爱思唯尔有限公司保留所有权利。
Plasmodium falciparum surface protein 25 (Pfs25) is a candidate for transmission-blocking vaccines (TBVs). Anti-Pfs25 antibodies block the development of oocysts in membrane-feeding assays and we have shown the activity correlates with antibody titer. In this study, we purified Pfs25-specific IgGs to convert antibody titer to p,mu g/mL and determined the amount of antibody required to inhibit 50% of oocyst development (IC50). The IC50 were, 15.9, 4.2, 41.2, and 85.6 mu g/mL for mouse, rabbit, monkey and human, respectively, and the differences among species were significant. Anti-Pfs25 sera from rabbit, monkey and human showed different patterns of competition against 6 mouse monoclonal antibodies, and the avidity of antibodies among four species were also different. These data suggests that information obtained from animal studies which assess efficacy of TBV candidates may be difficult to translate to human immunization. (C) 2010 Elsevier Ltd. All rights reserved.